BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female patients
Age = 18 years and = 70 years
Definite AS based on the modified New York criteria (1984)
Documented disease duration >= 3 months at screening
Active disease at screening, defined as:
BASDAI score (0-10) >= 4, AND
Spinal pain level assessed by the 2nd BASDAI question (0-10) >= 4
Have either a documented inadequate response for axial symptoms to 30 days of optimal daily doses of at least two non-steroidal anti-inflammatory drugs (NSAIDs), or documented intolerance to NSAIDs
Female patients who meet any of the following criteria from screening visit up to the End of Observation visit (EOO):
using adequate contraception, e.g. any of the following methods plus condom: implants, injectables, combined oral contraceptives, intrauterine device (IUD)
have a vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
surgically sterilised (including hysterectomy)
postmenopausal defined as at least 1 year of spontaneous Amenorrhea
Patients (males or females) receiving background MTX or Leflunomide therapy who are following the national regulatory guidelines regarding contraception
Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation
Radiographic evidence of total ankylosis of the spine at screening or before (spinal XRay examinations at screening visit/ during screening period are not mandatory ¿ see footnote 12 from Flow-Chart 1)
Patient previously treated with any biological immunomodulating agent for AS, either licensed or experimental
Previous or current participation in a clinical trial testing an investigational drug for AS within 12 weeks prior to randomization (any biological immunomodulating agents are excluded)
Usage of any investigational drug within 30 days prior to randomization or the planned use of an investigational drug during the course of the actual study
Active uveitis or inflammatory bowel disease at screening
Diagnosed psoriatic arthritis at screening, satisfying the modified New York criteria
Patients who had received intraarticular injection(s) with corticosteroids within 4 weeks prior to screening visit
Patients who must or wish to continue the intake of restricted medications (cf. Section 126.96.36.199) or any drug considered likely to interfere with the safe conduct of the study
Major surgery performed within 8 weeks prior to screening or planned within 12 months after screening (e.g. hip replacement)
Chronic or relevant acute infections including HIV, viral hepatitis and tuberculosis (positive tests for HIV, HBV/HCV at screening will be exclusionary)
For tuberculosis patients, they are not eligible according to the following screening criteria:
Have signs or symptoms suggestive of current active or latent TB upon medical history, physical examination and/or a chest radiograph (both posterior-anterior and lateral views, taken within 3 months prior to the first administration of study drug and read by a qualified radiologist)
Have history of latent or active TB prior to screening, except for patients who have documentation of having completed an adequate treatment regimen at least 6 months prior to the first administration of study agent
Have positive QuantiFERON-TB Gold In-Tube test within 2 months prior to or during screening, in which active TB has not been ruled out, except for patients with history of latent TB and documentation of having completed an adequate treatment regimen at least 6 months prior to the first administration of study agent
Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix
Evidence of current or previous clinically significant disease, medical condition other than AS, finding of the medical examination (including vital signs and ECG), or laboratory value at the screening visit outside the reference range that is of clinical relevance, that in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This criterion provides an opportunity for the investigator to exclude patients based on clinical judgment, even if other eligibility criteria are satisfied.
History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
History of alcohol abuse within last 12 months (intake of more than 30 g/day)